Abstract
The pathological DNA-specific B cells in Systemic lupus erythematosus are a logical target for a selected therapeutic intervention. It has been recently shown that complement receptor type 1 on human B and T-lymphocytes has suppressive activity. The cocrosslinking of this receptor with the B-cell receptor (BCR) inhibits B cell activation and proliferation and it could be an attractive new target for negative signal delivery. Experimental therapy in humans is limited by many restrictions. Severe combined immunodeficiency (SCID) mice, which lack both T and B lymphocytes and accept xenogenic cells have been used for human cell transfer for evaluating the pathogenesis of human SLE. We hypothesize that it may be possible to re-establish tolerance to native DNA in humanized SCID mice with cells transferred from SLE patients by administering to them a chimeric molecule, containing a monoclonal antibody against human inhibitory complement receptor type 1 coupled to a decapeptide DWEYSVWLSN that mimics DNA antigenically. These protein-engineered molecules are able to cocrosslink selectively the antigen receptors of B-cells possessing anti-native DNA specificity with the inhibitory surface receptors, thus delivering a strong suppressive signal.
Keywords: SCID models of SLE, Inhibitory B cell receptors, Chimeric molecules, erythematosus, xenogenic, chimeric, decapeptide, DWEYSVWLSN, proteinuria, quinacrine, chloroquine, Epratuzumab, Lymphostat-B, glomerulonephritis, Rituximab, immunoglobulin, lymphadenopathy, splenomegaly
Current Pharmaceutical Design
Title: Humanized SCID Mice Models of SLE
Volume: 17 Issue: 13
Author(s): Nikola Kerekov, Nikolina Mihaylova, Jozsef Prechl and Andrey Tchorbanov
Affiliation:
Keywords: SCID models of SLE, Inhibitory B cell receptors, Chimeric molecules, erythematosus, xenogenic, chimeric, decapeptide, DWEYSVWLSN, proteinuria, quinacrine, chloroquine, Epratuzumab, Lymphostat-B, glomerulonephritis, Rituximab, immunoglobulin, lymphadenopathy, splenomegaly
Abstract: The pathological DNA-specific B cells in Systemic lupus erythematosus are a logical target for a selected therapeutic intervention. It has been recently shown that complement receptor type 1 on human B and T-lymphocytes has suppressive activity. The cocrosslinking of this receptor with the B-cell receptor (BCR) inhibits B cell activation and proliferation and it could be an attractive new target for negative signal delivery. Experimental therapy in humans is limited by many restrictions. Severe combined immunodeficiency (SCID) mice, which lack both T and B lymphocytes and accept xenogenic cells have been used for human cell transfer for evaluating the pathogenesis of human SLE. We hypothesize that it may be possible to re-establish tolerance to native DNA in humanized SCID mice with cells transferred from SLE patients by administering to them a chimeric molecule, containing a monoclonal antibody against human inhibitory complement receptor type 1 coupled to a decapeptide DWEYSVWLSN that mimics DNA antigenically. These protein-engineered molecules are able to cocrosslink selectively the antigen receptors of B-cells possessing anti-native DNA specificity with the inhibitory surface receptors, thus delivering a strong suppressive signal.
Export Options
About this article
Cite this article as:
Kerekov Nikola, Mihaylova Nikolina, Prechl Jozsef and Tchorbanov Andrey, Humanized SCID Mice Models of SLE, Current Pharmaceutical Design 2011; 17 (13) . https://dx.doi.org/10.2174/138161211795703780
DOI https://dx.doi.org/10.2174/138161211795703780 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Human Plasma Proteins, IHRP (Acute Phase Protein) and PHBP (Serine Protease), Which Bind to Glycosaminoglycans
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Fluorescence-Guided Malignant Glioma Resections
Current Drug Discovery Technologies Pulmonary Hypertension: Role of Combination Therapy
Current Vascular Pharmacology Immunotherapy for Conformational Diseases
Current Pharmaceutical Design The Role of Toll-Like Receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: A New Promising Therapeutic Approach?
CNS & Neurological Disorders - Drug Targets Control of β-Site Amyloid Precursor Protein-Cleaving Enzyme-1 Expression by Protein Kinase C-λ/ι and Nuclear Factor κ-B
Current Alzheimer Research Insight into Tissue Unbound Concentration: Utility in Drug Discovery and Development
Current Drug Metabolism Small Molecule Natural Products and Alzheimer’s Disease
Current Topics in Medicinal Chemistry Down-regulation of MiR-138-5p Protects Chondrocytes ATDC5 and CHON-001 from IL-1 β-induced Inflammation <I>Via</I> Up-regulating SOX9
Current Pharmaceutical Design TRH/TRH-R1 Receptor Signaling in the Brain Medulla as a Pathway of Vagally Mediated Gut Responses During the Cephalic Phase
Current Pharmaceutical Design Drug Repurposing Using Similarity-based Target Prediction, Docking Studies and Scaffold Hopping of Lefamulin
Letters in Drug Design & Discovery Immune Modulation of Asian Folk Herbal Medicines and Related Chemical Components for Cancer Management
Current Medicinal Chemistry Antiretroviral Drugs to Prevent Mother-to-Child Transmission of HIV During Breastfeeding
Current HIV Research A Survey for Predicting Enzyme Family Classes Using Machine Learning Methods
Current Drug Targets GPER and ER: Estrogen Receptors with Distinct Biological Roles in Breast Cancer
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Predicting Type-I (Rate-Shift) Functional Divergence of Protein Sequences and Applications in Functional Genomics
Current Genomics Selenium Derivatives as Cancer Preventive Agents
Current Medicinal Chemistry - Anti-Cancer Agents Probiotics as Drugs Against Human Gastrointestinal Infections
Recent Patents on Anti-Infective Drug Discovery Nutritional Approaches to Modulate Oxidative Stress in Alzheimers Disease
Current Alzheimer Research Neurotrophins - From Pathophysiology to Treatment in Alzheimers Disease
Current Alzheimer Research